Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile.
Department of Biomedical Sciences, Humanitas University, Milan, Italy.|IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Milan, Italy.
Silvio
S
Danese
IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Milan, Italy.
Stefanos
S
Bonovas
Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France.
Laurent
L
Peyrin-Biroulet
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D019819:Budesonide / Q000008:administration & dosage*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D016503:Drug Delivery Systems; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D019804:Mesalamine / Q000627:therapeutic use*; D018570:Risk Assessment
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids; D019804:Mesalamine; D019819:Budesonide